Article Text

Download PDFPDF
Letter
Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD
  1. Rosanna Cannatelli,
  2. Francesca Ferretti,
  3. Stefania Carmagnola,
  4. Irene Maria Bambina Bergna,
  5. Maria Camilla Monico,
  6. Giovanni Maconi,
  7. Sandro Ardizzone
  1. Gastroenterology and Digestive Endoscopy Unit, Department of Biochemical and Clinical Sciences 'L Sacco', University of Milan, ASST Fatebenefratelli Sacco, Milano, Italy
  1. Correspondence to Dr Rosanna Cannatelli, Gastroenterology and Digestive Endoscopy Unit, Department of Biochemical and Clinical Sciences "L. Sacco", University of Milan, ASST Fatebenefratelli Sacco, Milano, Lombardia, Italy; cannatelli.rosanna{at}asst-fbf-sacco.it

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We have read with interest the recent papers of Kennedy et al 1 2 regarding the attenuated anti-SARS-CoV-2 antibody response in patients with IBD and the crucial role of the COVID-19 vaccine in this cohort. The COVID-19 vaccine has been recommended especially for the vulnerable population, including immune-mediated inflammatory diseases.3–5 Therefore, we explored the rate of adverse events (AEs) and the onset of GI symptoms after vaccination with different COVID-19 vaccines in a large cohort of patients with IBD.

In this prospective study, we collected data (demographic and clinical variables, COVID-19 vaccine type, local, systemic or allergic AEs, and GI symptoms) from 488 (mean age±SD 55.3±14.4 years, 44.9% male) patients with IBD (UC 50.4%, Crohn’s disease 47.8% and undetermined IBD 1.8%) on regular follow-up at our IBD unit who had been administered COVID-19 vaccination from June to July 2021.

The demographic characteristics are shown in table 1. AEs were reported by 228 patients (46.7%) (figure 1). The most common systemic AE after the first dose was malaise (16.4%), followed by headache (12.9%) and asthenia (10.5%). …

View Full Text

Footnotes

  • Contributors RC, FF, SA and GM: planning the study, drafting the article, statistical analysis and interpretation of data. All other authors: data collection and critical revision of the article for important intellectual content. All authors approved the final version of the manuscript including the authorship list.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.